Results 151 to 160 of about 25,818 (186)

Clinical features and prognosis of orbital inflammatory myofibroblastic tumor. [PDF]

Int J Ophthalmol
Li J, Xu LY, Wang N, Liu R, Zhao SF, Ren TT, Guo QH, Zhang B, Zhang H, Yan HH, Zhang YF, Ma JM.   +11 more
europepmc   +1 more source

Toxicity profiles of ROS1 tyrosine kinase inhibitors in advanced non-small cell lung cancer: a systematic review and proportional meta-analysis. [PDF]

Front Pharmacol
Jiang BX, Zeng JW, Yan JJ, Zhao LY.
europepmc   +1 more source

Crizotinib: A Novel Strategy to Reverse Immunosuppression in Melanoma by Targeting Lactate Transport. [PDF]

MedComm (2020)
Zhou Z, Zhang X, Zhu S, Liu W, Guo Y, Xiong S, Peng C, Chen X.   +7 more
europepmc   +1 more source

Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database. [PDF]

Sci Prog
Zhao W, Jin X, Li Y, Peng H, Jiang J.
europepmc   +1 more source

Targeting arachidonic acid-modulated autophagy: a novel axis in crizotinib resistance. [PDF]

Transl Lung Cancer Res
Tahir S.
europepmc   +1 more source

Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide. [PDF]

Oncol Rev
Santamaria F, Roberto M, Maltese G, Nicolella F, Torchia A, Buccilli D, Di Civita MA, Giancontieri P, Marinelli D, Cirillo A, Bianco V, Verrico M, Botticelli A, Santini D.   +13 more
europepmc   +1 more source

Targeting MET and KRAS G12C co-occurring mutation in metastatic adenoid cystic carcinoma of the trachea: a case report. [PDF]

J Med Case Rep
Zhang L, Wang T, Xu Y, Ji Y, Nie K.
europepmc   +1 more source

Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study. [PDF]

J Am Heart Assoc
Lin CY, Su PL, Kuo CW, Tsai IL, Liu TH, Yang J, Lin CC, Lin SH.   +7 more
europepmc   +1 more source